United Therapeutics Corporation

DB:UTH Stock Report

Market Cap: €18.8b

United Therapeutics Valuation

Is UTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: UTH (€442.2) is trading below our estimate of future cash flow value (€1853.65)

Significantly Below Future Cash Flow Value: UTH is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UTH?

Key metric: As UTH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UTH. This is calculated by dividing UTH's market cap by their current earnings.
What is UTH's PE Ratio?
PE Ratio16.8x
EarningsUS$1.31b
Market CapUS$22.01b

Price to Earnings Ratio vs Peers

How does UTH's PE Ratio compare to its peers?

The above table shows the PE ratio for UTH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38x
SRT3 Sartorius
85.6x20.31%€15.3b
MRK Merck KGaA
25.4x11.68%€60.0b
INCY Incyte
16.1x-5.15%US$25.9b
GMAB Genmab
24.8x19.54%DKK 128.4b
UTH United Therapeutics
16.8x15.60%€22.0b

Price-To-Earnings vs Peers: UTH is good value based on its Price-To-Earnings Ratio (16.8x) compared to the peer average (38.4x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does UTH's PE Ratio compare vs other companies in the European Biotechs Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
UTH 16.8xIndustry Avg. 23.1xNo. of Companies7PE020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UTH is good value based on its Price-To-Earnings Ratio (16.8x) compared to the European Biotechs industry average (23.1x).

Price to Earnings Ratio vs Fair Ratio

What is UTH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UTH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.8x
Fair PE Ratio37.4x

Price-To-Earnings vs Fair Ratio: UTH is good value based on its Price-To-Earnings Ratio (16.8x) compared to the estimated Fair Price-To-Earnings Ratio (37.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UTH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€435.90
€568.94
+30.52%
9.00%€620.89€441.05n/a12
Aug ’27€454.50
€582.91
+28.25%
10.69%€659.18€453.51n/a13
Jul ’27€471.60
€582.21
+23.45%
10.79%€656.40€451.60n/a13
Jun ’27€474.20
€570.24
+20.25%
10.79%€642.90€442.32n/a13
May ’27€485.80
€549.92
+13.20%
10.44%€625.32€442.76n/a13
Apr ’27€516.60
€539.52
+4.44%
11.22%€634.19€407.51n/a12
Mar ’27€427.30
€481.74
+12.74%
10.68%€554.06€394.19n/a12
Feb ’27€391.80
€446.80
+14.04%
12.16%€542.90€356.04n/a12
Jan ’27€427.10
€442.64
+3.64%
11.21%€512.46€361.28n/a12
Dec ’26€416.80
€449.58
+7.87%
11.21%€520.50€366.95n/a12
Nov ’26€392.30
€442.21
+12.72%
11.07%€507.52€365.73n/a13
Oct ’26€373.20
€413.36
+10.76%
15.52%€494.57€279.69n/a13
Sep ’26€257.80
€324.89
+26.02%
15.50%€435.39€251.84n/a12
Aug ’26€238.10
€325.42
+36.67%
15.64%€440.44€254.76€454.5012
Jul ’26€241.60
€322.46
+33.47%
14.93%€432.58€266.33€471.6013
Jun ’26€281.40
€342.49
+21.71%
19.96%€529.38€277.04€474.2012
May ’26€261.40
€343.81
+31.53%
19.96%€531.42€278.11€485.8012
Apr ’26€283.60
€363.55
+28.19%
18.83%€556.14€271.58€516.6013
Mar ’26€308.90
€386.20
+25.02%
17.67%€578.52€282.51€427.3013
Feb ’26€343.00
€386.23
+12.60%
17.75%€576.24€290.04€391.8013
Jan ’26€341.80
€375.15
+9.76%
17.10%€571.68€287.75€427.1014
Dec ’25€364.80
€367.05
+0.62%
20.42%€576.18€212.23€416.8015
Nov ’25€341.70
€351.48
+2.86%
21.13%€551.64€203.19€392.3014
Oct ’25€319.20
€320.83
+0.51%
23.14%€517.44€198.88€373.2014
Sep ’25€328.00
€315.53
-3.80%
23.61%€517.33€198.83€257.8013
Aug ’25€289.10
€308.39
+6.67%
15.87%€370.68€204.80€238.1013
€572.51
Fair Value
22.8% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/24 22:34
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

United Therapeutics Corporation is covered by 33 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
James BirchenoughBarclays
Derek TallerBenchmark Company